The Evolving Role of Positron Emission Tomography in Patients with Medullary Thyroid Carcinoma

PET Clinics

Volumn 2, Issue 3, 2007, Pages 305-311

  Urhan, Muammer ^a   Alavi, Abass ^b   Nanni, Cristina ^c  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

F DOPA; FDG; Medullary thyroid cancer; Positron emission tomography

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER STAGING; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

EID: 64749097617     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2008.04.006     Document Type: Review

References (64)

1. Bustros A.C., and Baylin S.B. Medullary carcinoma of thyroid. In: Braverman L.E., and Utiger R.D. (Eds). Werner and Ingbar's the thyroid (1991), JB Lippincott Company, New York 1167
2. Modigliani E., Cohen R., Campos J.M., et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Group d'etude des tumeurs a calcitonine. Clin Endocrin (Oxf) 48 (1998) 265-273
3. Correa P., and Chen V.W. Endocrine gland cancer. Cancer 75 (1995) 338-352
4. Marsh D.J., Learoyd D.L., and Robinson B.G. Medullary thyroid carcinoma: recent advances and management update. Thyroid 5 (1995) 407-424
5. O'Riordain D.S., O'Brien T., Weaver A.L., et al. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116 (1994) 1017-1023
6. Saad M.F., Ordonez N.G., Rashid R.K., et al. Medullary carcinoma of the thyroid: a study of the clinical and prognostic factors in 161 patients. Medicine 63 (1984) 319-342
7. Lairmore T.C., and Wells Jr. S.A. Medullary carcinoma of the thyroid: current diagnosis and management. Semin Surg Oncol 7 (1991) 92-99
8. Grauer A., Raue F., and Gagel R. Changing concepts in the management of hereditary and sporadic medullary carcinoma. Endocrinol Metab Clin North Am 19 (1990) 613-635
9. Abdelmoumene N., Schlumberger M., Gardet P., et al. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 69 (1994) 1141-1144
10. Raue F., Winter J., Frank-Raue K., et al. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 21 (1989) 31-34
11. Frank-Raue K., Raue F., Buhr H.J., et al. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid 2 (1992) 113-117
12. Norton J.A., Doppman J.L., and Brennan M.F. Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 87 (1980) 616-622
13. Simeone J.F., Daniels G.H., Hall D.A., et al. Sonography in the follow-up of 100 patients with thyroid carcinoma. AJR Am J Roentgenol 148 (1987) 45-49
14. Auffermann W., Clark O.H., Thurnber S., et al. Recurrent thyroid carcinoma: characteristics on MR images. Radiology 168 (1988) 753-757
15. Crow J.P., Azar-Kia B., and Prinz R.A. Recurrent occult medullary thyroid carcinoma detected by MR imaging. AJR Am J Roentgenol 152 (1989) 1255-1256
16. Wang Q., Takashima S., Fukuda H., et al. Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 125 (1999) 842-848
17. Stomper P.L. Cancer imaging manual (1993), Lippincott, Philadelphia p. 51-60
18. Dörr U., Würstlin S., Frank-Raue K., et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Horm Metab Res Suppl 27 (1993) 48-55
19. Baudin E., Lumbroso J., Schlumberger M., et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 37 (1996) 912-916
20. Behr T.M., Gotthardt M., Barth A., et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 45 (2001) 189-200
21. Krausz Y., Rosler A., Guttmann H., et al. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 24 (1999) 256-260
22. Berna L., Chico A., Matias-Guiu X., et al. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med 25 (1998) 1482-1488
23. Arslan N., Ilgan S., Yuksel D., et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med 26 (2001) 683-688
24. Berna L., Cabezas R., Mora J., et al. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144 (1995) 339-345
25. Limouris G.S., Giannakopoulos V., Stavraka A., et al. Comparison of In-111 pentetreotide, Tc-99m (V)-DMSA and I-123 MlBG scintimaging in neural crest tumors. Anticancer Res 17 (1997) 1589-1592
26. Thomas C.C., Cowan R.J., Albertson D.A., et al. Detection of medullary carcinoma of the thyroid with I-131 MIBG. Clin Nucl Med 19 (1994) 1066-1068
27. Troncone L., Rufini V., Montemaggi P., et al. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG): 5 years of experience. Eur J Nucl Med 16 (1990) 325-335
28. Learoyd D.L., Roach P.J., Briggs G.M., et al. Technetium-99-sestamibi scanning in recurrent medullary thyroid carcinoma. J Nucl Med 38 (1997) 227-230
29. 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23 (1996) 1367-1371
30. Hoefnagel C.A., Delprat C.C., Zanin D., et al. New radionuclide tracers for the diagnosis and therapy of the medullary thyroid carcinoma. Clin Nucl Med 13 (1988) 159-165
31. Manil L., Boudet F., Motte P., et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma. Cancer Res 49 (1989) 5480-5485
32. Reiners C., Eilles C., Spiegel W., et al. Immunoscintigraphy in medullary thyroid cancer using an 123I- or 111In-labelled monoclonal anti-CEA antibody fragment. Nuklearmedizin 25 (1986) 227-231
33. Peltier P., Curtet C., Chatal J.-F., et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 34 (1993) 1267-1273
34. Behr T.M., Jenner N., Radetzky S., et al. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnosis and therapeutic potential of radiolabelled gastrin. Eur J Nucl Med 25 (1998) 424-430
35. Behr T.M., Jenner J., Behe M., et al. Radiolabelled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 40 (1999) 1029-1040
36. Strauss L.G., and Conti P.S. The application of PET in clinical oncology. J Nucl Med 32 (1991) 623-648
37. Gasparoni P., Rubello D., and Ferlin G. Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 20 (1997) 527-530
38. Diehl M., Risse J.H., Brandt-Mainz K., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: result of a multicenter study. Eur J Nucl Med 28 (2001) 1671-1676
39. Grünwald F., Kälicke T., Feine U., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicenter study. Eur J Nucl Med 26 (1999) 1547-1552
40. Rufini V., Salvatori M., Garganese M.C., et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25 (2000) 273-282
41. de Groot J.W., Links T.P., Jager P.L., et al. Impact of F-18 fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11 8 (2004) 786-794
42. Brandt-Mainz K., Muller S.P., Gorges R., et al. The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27 (2000) 490-496
43. Szakall Jr. S., Esik O., Balzik G., et al. F-18 FDG-PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43 1 (2002) 66-71
44. Crippa F., Alessi A., Gerali A., et al. FDG-PET in thyroid cancer. Tumori 89 (2003) 540-543
45. Conti P.S., Lilien D.L., Hawley K., et al. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 23 (1996) 717-735
46. Bockish A., Brandt-Mainz K., Görges R., et al. Diagnosis in medullary thyroid cancer with F-18 FDG-PET and improvent using a combined PET/CT scanner. Acta Med Austriaca 30 (2003) 22-25
47. Iagaru A., Masamed R., Singer P.A., et al. Detection of occult medullary thyroid cancer recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT. Mol Imaging Biol 9 (2007) 72-77
48. Adams S., Baum R., Rink T., et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography fort the imaging neuroendocrine tumors. Eur J Nucl Med 25 (1998) 79-83
49. Okada J., Oonishi H., Yoshikawa K., et al. FDG-PET for predicting the prognosis of malignant lymphoma. Ann Nucl Med 8 (1994) 187-191
50. Feine U., Lietzenmayer R., Hanke J.P., et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
51. Musholt T.J., Musholt P.B., Dehdashti F., et al. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122 (1997) 1049-1060 [discussion: 1060-1]
52. Conti P.S., Durski J.M., Bacqai F., et al. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9 (1999) 797-804
53. Bergström M., Erikson B., Öberg K., et al. In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 37 (1996) 32-37
54. Pearse A.G. The cytochemistry and ultrastructure of polypeptide hormone producing cells of APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 17 (1969) 303-308
55. Jager P.L., Vaalburg W., Pruim J., et al. Radiolabelled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-435
56. Ahlström H., Erikson B., Bergström M., et al. Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195 (1995) 333-337
57. Orlefors H., Sundin A., Ahsltröm H., et al. Positron emission tomography with 5-hydroxytriptophan in neuroendocrine tumors. J Clin Oncol 16 (1998) 2534-2541
58. Hoegerle S., Schneider B., Kraft A., et al. Imaging of a metastatic gastrointestinal carcinoid by F-18-DOPA positron emission tomography. Nuklearmedizin 38 (1999) 127-130
59. Hoegerle S., Altehoefer C., Ghanem N., et al. F-18 DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28 (2001) 64-71
60. Beuthien-Baumann B., Strumpf A., Zessin J., et al. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl -6-18F-fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34 (2007) 1604-1609
61. Beuthien-Baumann B., Bredow J., Burchert W., et al. 3-O-methyl -6-18F-fluoro-L-DOPA and its evaluation in brain tumor imaging. Eur J Nucl Med Mol Imaging 30 (2003) 1004-1008
62. Feine U., Lietzenmayer R., Scheidhauer K., et al. Fluorine-18-FDG and iodine-131 uptake in thyroid cancer. J Nucl Med 37 (1996) 1468-1472
63. Gourgiotis L., Sarlis N.J., Reynolds J.C., et al. Localization of medullary thyroid carcinoma metastasis in a multiple endocrine neoplasia type 2A patient by 6-F-18 fluorodopamine positron emission tomography. J Clin Endocrinol Metab 88 2 (2003) 637-641
64. Oishi S., Sasaki M., Sato T., et al. Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma. Endocrinol Jpn 33 3 (1986) 309-315